BIOTA PHARMACEUTICALS INC | 2,801 Euro | -0,041 -1,44 % | |
| WKN: A1J7ZV ISIN: US0906941002 Ticker-Symbol: NB1N | Frankfurt | 23.05.13 | 18:43 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 22.05. | Nabi Biopharmaceuticals is Among the Companies in the Biotechnology Industry With the Lowest Operating Margin | 3 | SmarTrend | |
| 10.05. | Biota Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | |
| 08.05. | NABI to suspend production at plant at end of May | 2 | BBJ online | |
| 15.04. | Biota Pharmaceuticals relos HQ to Atlanta | 3 | bizjournals | |
| 04.04. | B'IOTA BOTANICALS Provides U.S. Consumers With Clinically-Shown Herbal Products for Thinning Hair / When It Comes to Hair, Thin Is Definitely Not in | 29 | Marketwired | |
| GREENWICH, CT -- (Marketwired) -- 04/04/13 -- The new trend in hair care is not a cut, or a color, or a style. Instead, it is the promise of thicker, fuller-looking hair. One of the biggest hair issues... Mehr lesen zu: B'IOTA BOTANICALS Provides U.S. Consumers With Clinically-Shown Herbal Products for Thinning Hair / When It Comes to Hair, Thin Is Definitely Not in | ||||
| 12.02. | B'IOTA Botanicals' Entry Into U.S. Market Provides Clinically-Proven, Herbal Solution for People With Thinning Hair | 58 | Marketwired | |
| GREENWICH, CT -- (Marketwire) -- 02/12/13 -- After more than a decade of success in over 35 countries, B'IOTA (Bee-Oh-Tah) BOTANICALS, the leading and trusted European expert brand in herbal hair-... Mehr lesen zu: B'IOTA Botanicals' Entry Into U.S. Market Provides Clinically-Proven, Herbal Solution for People With Thinning Hair | ||||
| 12.02. | Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update | 36 | Marketwired | |
| ROCKVILLE, MD -- (Marketwire) -- 02/12/13 -- Biota Pharmaceuticals, Inc. (NASDAQ: BOTA)
LANI Influenza Program Advancing Toward Phase 2 Clinical Development
Merger between Nabi Biopharmaceuticals... Mehr lesen zu: Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update | ||||
| 12.12. | Fuhu, Inc. Unveils nabi(R) XD: The World's First Android Ultraportable for Tweens at $249 / Fuhu, Inc. Defines a New Market for Tablet Users With Its Nabi XD, Positioned as a Tween's First Tablet With a Keyboard Dedicated to Homework, Gaming, Socia | 66 | Marketwired | |
| EL SEGUNDO, CA -- (Marketwire) -- 12/12/12 -- Fuhu, Inc., the leader in tablets made just for kids, today unveiled the new nabi® XD: an ultraportable tablet that combines the best of a notebook and... Mehr lesen zu: Fuhu, Inc. Unveils nabi(R) XD: The World's First Android Ultraportable for Tweens at $249 / Fuhu, Inc. Defines a New Market for Tablet Users With Its Nabi XD, Positioned as a Tween's First Tablet With a Keyboard Dedicated to Homework, Gaming, Socia | ||||
| 16.11. | XFRA NB1N: WIEDERAUFNAHME/RESTART | 754 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE WIRD MIT SOFORTIGER WIRKUNG WIEDER IN DEN HANDEL
AUFGENOMMEN:
THE FOLLOWING SHARE IS RESUMED TRADING WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
Biota Pharmaceuticals... Mehr lesen zu: XFRA NB1N: WIEDERAUFNAHME/RESTART | ||||
| 14.11. | Biota Pharmaceuticals Announces Appointment of New Executive Officers | 90 | Marketwired | |
| ROCKVILLE, MD -- (Marketwire) -- 11/14/12 -- Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) today announced the appointment of Russell H. Plumb as its Chief Executive Officer and Joseph M. Patti, M.S.P.H.... Mehr lesen zu: Biota Pharmaceuticals Announces Appointment of New Executive Officers | ||||
| 12.11. | XFRA NB1N: AUSSETZUNG/SUSPENSION | 182 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
Biota Pharmaceuticals Inc. NB1N US0906941002... Mehr lesen zu: XFRA NB1N: AUSSETZUNG/SUSPENSION | ||||
| 12.11. | XFRA FRA:New Instruments available on XETRA - 12.11.2012-001 | 332 | Xetra Newsboard | |
| The following instruments on XETRA do have their first trading day
12.11.2012
Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am
12.11.2012
TrdMod InstCode Exch ISIN Name InstGrp... Mehr lesen zu: XFRA FRA:New Instruments available on XETRA - 12.11.2012-001 | ||||
| 09.11. | XFRA E8K,NB1: AENDERUNG / CHANGE ISIN | 688 | Xetra Newsboard | |
| FUER FOLGENDE INSTRUMENTE WERDEN ISIN, WKN UND KUERZEL GEAENDERT, GUELTIG
AB 12.11.2012
FOR THE FOLLOWING INSTRUMENTS ISIN, WKN AND SHORT CODE WILL CHANGE, VALID
FROM NOVEMBER 12, 2012
EINSTELLUNG... Mehr lesen zu: XFRA E8K,NB1: AENDERUNG / CHANGE ISIN | ||||
| 09.11. | XFRA NB1: AUSSETZUNG/SUSPENSION | 84 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
NABI BIOPHARMACEUTICALS NB1 US6295191091 B... Mehr lesen zu: XFRA NB1: AUSSETZUNG/SUSPENSION | ||||
| 09.11. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.11.2012 - 2 | 294 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 09.11.2012 EX KAPITALMASSNAHME GEHANDELT.
THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 09.11.2012.
INSTR EXCH ISIN INSTRUMENT NAME
3VIA XFRA US9215641005... Mehr lesen zu: XFRA CAPITAL ADJUSTMENT INFORMATION - 09.11.2012 - 2 | ||||
| 23.10. | Biota Announces Shareholder Approval of Merger With Nabi Pharmaceuticals | 73 | Marketwired | |
| MELBOURNE, AUSTRALIA -- (Marketwire) -- 10/23/12 -- Biota Holdings Limited (ASX: BTA) today announced shareholder approval of a merger with Nabi Biopharmaceuticals to create the combined company, Biota... Mehr lesen zu: Biota Announces Shareholder Approval of Merger With Nabi Pharmaceuticals | ||||
| 23.10. | Biota Announces Approval of Definitive Merger Agreement by Nabi Shareholders | 62 | Marketwired | |
| MELBOURNE, AUSTRALIA -- (Marketwire) -- 10/23/12 -- Biota Holdings Limited (ASX: BTA) (Biota) announces that the shareholders of Nabi Biopharmaceuticals Inc. (Nabi) have approved proposals related... Mehr lesen zu: Biota Announces Approval of Definitive Merger Agreement by Nabi Shareholders | ||||
| 17.10. | XFRA NB1: WIEDERAUFNAHME/RESTART | 64 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE WIRD MIT SOFORTIGER WIRKUNG WIEDER IN DEN HANDEL
AUFGENOMMEN:
THE FOLLOWING SHARE IS RESUMED TRADING WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
Nabi Biopharm.... Mehr lesen zu: XFRA NB1: WIEDERAUFNAHME/RESTART | ||||
| 17.10. | XFRA NB1: AUSSETZUNG/SUSPENSION | 64 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
Nabi Biopharm. NB1 US6295191091 BAW/UFN Mehr lesen zu: XFRA NB1: AUSSETZUNG/SUSPENSION | ||||
| 20.09. | Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings | 61 | PR Newswire | |
| NEW YORK, Sept. 19, 2012 /PRNewswire/ --The Mangrove Partners Fund, L.P. ("Mangrove Partners"), one of the largest stockholders of Nabi Biopharmaceuticals (NasdaqGS: NABI), announced today that it... Mehr lesen zu: Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| EVOTEC | 2,766 | -2,50 % | Evotec-Aktie: Jetzt einsteigen! |
| QIAGEN | 14,495 | -1,16 % | Qiagen und SYGNIS Pharma schließen Lizenzvertrag |
| MEDIGENE | 0,889 | -1,22 % | Medigene-Aktie feiert Studienergebnisse mit EndoTAG |
| MOLOGEN | 13,705 | -1,76 % | Mologen: Marginales Plus |
| DENDREON | 3,046 | -2,15 % | Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Settlement in the In re Dendreon Corporation Class Action Litigation |
